STREAM: Statin Discontinuation Noninferior in Older Adults Without CVD

The STREAM trial, presented at the American Heart Association's Scientific Sessions, found that discontinuing statin therapy in adults over 70 without prior cardiovascular disease is noninferior to continuing it. However, researchers noted a slight increase in cardiovascular events, suggesting that medication decisions should be made on an individual basis.
Why it matters
This study provides important data for geriatric care, potentially reducing unnecessary medication use in older populations while highlighting the need for personalized medical decision-making.
Discontinuing statin therapy was noninferior to continuation for nonfatal myocardial infarction (MI), nonfatal ischemic stroke, or death at 2 years in adults aged 70 years or older with multiple chronic conditions and no known atherosclerotic cardiovascular disease, according to STREAM trial results presented at the American Heart Association (AHA) Scientific Sessions 2026 and published in the New England Journal of Medicine.1
The 2-year restricted mean event-free survival time was 96.5 weeks with discontinuation and 98.5 weeks with continuation, a difference of −2.0 weeks (95% CI, −3.7 to −0.3; P < .001 for noninferiority) within the prespecified −5.2-week margin.1
Over a median follow-up of 103 weeks, the primary outcome occurred in 12.7% (119/938) of the discontinuation group and 9.2% (87/942) of the continuation group (hazard ratio [HR], 1.38; 95% CI, 1.05–1.81). The investigators estimated 1 additional major cardiovascular event or death over 2 years for every 40 people who stopped statins.1
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in